Journal of Food and Nutrition Research
ISSN (Print): 2333-1119 ISSN (Online): 2333-1240 Website: http://www.sciepub.com/journal/jfnr Editor-in-chief: Prabhat Kumar Mandal
Open Access
Journal Browser
Go
Journal of Food and Nutrition Research. 2019, 7(4), 287-290
DOI: 10.12691/jfnr-7-4-5
Open AccessArticle

Effect of Genistein on Interleukin 1β and Transforming Growth Factor β in Diabetic Rat

Putri Dafriani1, , Nur Indrawati Lipoeto2, Honesty Diana Morika3, Eliza Arman1, Weni Sartiwi3 and Annita1

1Biomedic, Sekolah Tinggi Ilmu Kesehatan Syedza Saintika, Padang, Indonesia

2Nutrition, Universitas Andalas, Padang, Indonesia

3Nursing, Sekolah Tinggi Ilmu Kesehatan Syedza Saintika, Padang, Indonesia

Pub. Date: April 05, 2019

Cite this paper:
Putri Dafriani, Nur Indrawati Lipoeto, Honesty Diana Morika, Eliza Arman, Weni Sartiwi and Annita. Effect of Genistein on Interleukin 1β and Transforming Growth Factor β in Diabetic Rat. Journal of Food and Nutrition Research. 2019; 7(4):287-290. doi: 10.12691/jfnr-7-4-5

Abstract

One of diabetic complications is diabetes nephropathy. Nephropathy is caused by oxidative stress. Oxidative stress causes an inflammatory response that continues to the kidney fibrosis. Genistein can reduce proinflammatory citokines. This study aims to examine the effect of genistein on levels of IL-1β, TGF-β, HSP 47 and type IV collagen. This study was experimental. This study use 25 male wistar rats as experimental animals. Rats were divided into five groups, normal rats , hyperglycemic rats, hyperglycemic rats with administration of genistein 0.5 mg/kgw, hyperglycemic rats with administration of genistein 1 mg/kgw, hyperglycemic rats with genistein 2 mg/kgw. Streptozotocin given 65 mg/kgw by intraperitonal injection. The duration of administration of genistein is 4 weeks. The average levels of IL-1β in non-diabetic control group was 181.436 pg/ml, diabetic control 359.303 pg/ml, STZ: G 0.5 mg/kgw 265.088 pg/ml, STZ; G 1 mg/kgw 240.088 pg/ml and STZ; G 2 mg/kgw 120.344 pg/ml with p value of 0.000 (p < 0.05), it means that there is the effect of genistein on the levels of IL-1β in diabetic. The average levels of TGF-β in non diabetic control group was 1411.462 pg/ml, diabetic control 8492.520 pg/ml, STZ; G 0.5 mg/kgw 7334.098 pg/ml, STZ; G 1 mg/kgw 6134.568 pg/ml and STZ; G 2 mg/kgw 5012.616 pg/ml with p value of 0.000 (p < 0.05), which means that there is the effect of genistein on the levels of TGF-β. Genistein can reduce fibrosis by reducing levels of IL-1β and TGF-β.

Keywords:
genistein interleukin 1β TGF-β diabetic nephropathy

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  D. K. Packham et al., “Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: Results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database,” American Journal of Kidney Diseases, vol. 59, no. 1. pp. 75-83, 2012.
 
[2]  E. B. Byun et al., “Anti-inflammatory effect of gamma-irradiated genistein through inhibition of NF-κB and MAPK signaling pathway in lipopolysaccharide-induced macrophages,” Food Chem. Toxicol., vol. 74, pp. 255-264, 2014.
 
[3]  X. Dong, W. Xu, R. A. Sikes, and C. Wu, “Combination of low dose of genistein and daidzein has synergistic preventive effects on isogenic human prostate cancer cells when compared with individual soy isoflavone,” Food Chem., vol. 141, no. 3, pp. 1923-1933, 2013.
 
[4]  D. S. Lee and S. H. Lee, “Genistein, a soy isoflavone, is a potent α-glucosidase inhibitor,” FEBS Lett., vol. 501, no. 1, pp. 84-86, 2001.
 
[5]  S. P. Srivastava, D. Koya, and K. Kanasaki, “MicroRNAs in kidney fibrosis and diabetic nephropathy: Roles on EMT and EndMT,” BioMed Research International, vol. 2013. 2013.
 
[6]  S. C. Mishra, K. C. Chhatbar, A. Kashikar, and A. Mehndiratta, “Diabetic foot,” pp. 1-7.
 
[7]  A. A. Elmarakby, A. S. Ibrahim, J. Faulkner, M. S. Mozaffari, G. I. Liou, and R. Abdelsayed, “Tyrosine kinase inhibitor, genistein, reduces renal inflammation and injury in streptozotocin-induced diabetic mice,” Vascular Pharmacology, vol. 55, no. 5-6. pp. 149-156, 2011.
 
[8]  D. K. Patel, S. K. Prasad, R. Kumar, and S. Hemalatha, “An overview on antidiabetic medicinal plants having insulin mimetic property,” Asian Pacific Journal of Tropical Biomedicine, vol. 2, no. 4. pp. 320-330, 2012.
 
[9]  M. Lech and H. J. Anders, “Macrophages and fibrosis: How resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair,” Biochim. Biophys. Acta - Mol. Basis Dis., vol. 1832, no. 7, pp. 989-997, 2013.
 
[10]  P. Dafriani, N. I. Lipoeto, A. Bakhtiar, and R. Marlinda, “Effect of Genistein on Heat Shock Protein 47 and Collagen Type IV in Diabetic Rat,” pp. 163-167, 2018.
 
[11]  P. Sthaneshwar and S. P. Chan, “Urinary type IV collagen levels in diabetes mellitus,” Malays. J. Pathol., vol. 32, no. 1, pp. 43-47, 2010.
 
[12]  S. Shafi, N. Tabassum, and F. Ahmad, “Diabetic nephropathy and herbal medicines,” vol. 3. pp. 10-17, 2012.
 
[13]  Z. Yang, K. Kulkarni, W. Zhu, and M. Hu, “Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME.,” Anti-cancer agents in medicinal chemistry, vol. 12, no. 10. pp. 1264-80, 2012.
 
[14]  A. K. H. Lim and G. H. Tesch, “Inflammation in diabetic nephropathy,” Mediators of Inflammation, vol. 2012. 2012.
 
[15]  N. Behloul and G. Wu, “Genistein: A promising therapeutic agent for obesity and diabetes treatment,” Eur. J. Pharmacol., vol. 698, no. 1-3, pp. 31-38, 2013.
 
[16]  E. K. Kim et al., “Genistein protects pancreatic?? cells against cytokine-mediated toxicity,” Mol. Cell. Endocrinol., vol. 278, no. 1-2, pp. 18-28, 2007.
 
[17]  N. Kotajima et al., “Type IV collagen as an early marker for diabetic nephropathy in non-insulin-dependent diabetes mellitus.,” J. Diabetes Complications, vol. 14, no. 1, pp. 13-7, 2000.
 
[18]  S. Cui, N. Wienhoefer, and U. Bilitewski, “Genistein induces morphology change and G2/M cell cycle arrest by inducing p38 MAPK activation in macrophages,” Int. Immunopharmacol., vol. 18, no. 1, pp. 142-150, 2014.
 
[19]  A. Manuscript, T. Growth, and F. Beta, “NIH Public Access,” vol. 32, no. 3, pp. 295-303, 2013.
 
[20]  H. Y. Lan, “Diverse Roles of TGF- β / Smads in Renal Fibrosis and Inflammation.” 2011.
 
[21]  D. Pohlers et al., “TGF-β and fibrosis in different organs - molecular pathway imprints,” Biochim. Biophys. Acta - Mol. Basis Dis., vol. 1792, no. 8, pp. 746-756, 2009.
 
[22]  A. Manuscript and I. Proximity, “NIH Public Access,” vol. 4, no. 164, pp. 153-160, 2011.
 
[23]  S. Yu, X. Xing, G. Dong, X. Weng, and M. Wang, “Excess genistein suppresses the synthesis of extracellular matrix in female rat mandibular condylar cartilage,” Acta Pharmacologica Sinica, vol. 33, no. 7. pp. 918-923, 2012.
 
[24]  Z. Jia et al., “Genistein inhibits TNF- α -induced endothelial in fl ammation through the protein kinase pathway A and improves vascular in fl ammation in C57BL / 6 mice,” Int. J. Cardiol., vol. 168, no. 3, pp. 2637-2645, 2013.